We can’t show the full text here under this license. Use the link below to read it at the source.
The Composite Number Needed to Treat for Semaglutide in Populations with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes
Number Needed to Treat with Semaglutide for People with Overweight or Obesity and Heart Disease but No Diabetes
AI simplified
Abstract
The (NNT) for semaglutide to prevent major adverse cardiovascular events significantly decreased from 125 at 1 year to 58 at 4 years.
- Relative risk reductions for major adverse cardiovascular events (MACE) were observed at 20% for both primary and extended NNTs and 41% for the broader outcomes.
- NNT estimates decreased when including additional outcomes such as hospitalization and kidney health, indicating a broader treatment benefit.
- At 4 years, the NNT for the extended outcomes was 11, suggesting a more favorable treatment effect over time.
- These findings indicate that evaluating semaglutide's effects beyond the primary endpoint may provide greater value for stakeholders.
AI simplified
Key numbers
125
for Primary Endpoint
Calculated from the primary CV composite endpoint of the SELECT trial.
49
with Broader Outcomes
Includes hospitalization and diabetes progression in calculations.
11
Reduction at 4 Years
Shows the cumulative benefit of semaglutide treatment over 4 years.